Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19
Keith Sacco,Riccardo Castagnoli,Svetlana Vakkilainen,Can Liu,Ottavia M. Delmonte,Cihan Oguz,Ian M. Kaplan,Sara Alehashemi,Peter D. Burbelo,Farzana Bhuyan,Adriana A. de Jesus,Kerry Dobbs,Lindsey B. Rosen,Aristine Cheng,Elana Shaw,Mikko S. Vakkilainen,Francesca Pala,Justin Lack,Yu Zhang,Danielle L. Fink,Vasileios Oikonomou,Andrew L. Snow,Clifton L. Dalgard,Jinguo Chen,Brian A. Sellers,Gina A. Montealegre Sanchez,Karyl Barron,Emma Rey-Jurado,Cecilia Vial,Maria Cecilia Poli,Amelia Licari,Daniela Montagna,Gian Luigi Marseglia,Francesco Licciardi,Ugo Ramenghi,Valentina Discepolo,Andrea Lo Vecchio,Alfredo Guarino,Eli M. Eisenstein,Luisa Imberti,Alessandra Sottini,Andrea Biondi,Sayonara Mató,Dana Gerstbacher,Meng Truong,Michael A. Stack,Mary Magliocco,Marita Bosticardo,Tomoki Kawai,Jeffrey J. Danielson,Tyler Hulett,Manor Askenazi,Shaohui Hu,Jeffrey I. Cohen,Helen C. Su,Douglas B. Kuhns,Michail S. Lionakis,Thomas M. Snyder,Steven M. Holland,Raphaela Goldbach-Mansky,John S. Tsang,Luigi D. Notarangelo,Jason Barnett,Xi Cheng,Krishnaveni Kaladi,Vasudev Kuram,Joseph Mackey,Neha M. Bansal,Andrew J. Martins,Boaz Palterer,Helen Matthews,Uma Mudunuri,Marshall Nambiar,Andrew J. Oler,Andre Rastegar,Smilee Samuel,Conrad Shyu,Varsha Waingankar,Sarah Weber,Sandhya Xirasagar,Yazmin Espinosa,Camila Astudillo,Cecilia Piñera,Ricardo González,Maria De Filippo,Martina Votto,Lorenza Montagna,,,
DOI: https://doi.org/10.1038/s41591-022-01724-3
IF: 82.9
2022-02-17
Nature Medicine
Abstract:Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might develop multisystem inflammatory syndrome in children (MIS-C), with substantial morbidity. In this longitudinal multi-institutional study, we applied multi-omics (analysis of soluble biomarkers, proteomics, single-cell gene expression and immune repertoire analysis) to profile children with COVID-19 (n = 110) and MIS-C (n = 76), along with pediatric healthy controls (pHCs; n = 76). pCOVID-19 was characterized by robust type I interferon (IFN) responses, whereas prominent type II IFN-dependent and NF-κB-dependent signatures, matrisome activation and increased levels of circulating spike protein were detected in MIS-C, with no correlation with SARS-CoV-2 PCR status around the time of admission. Transient expansion of TRBV11-2 T cell clonotypes in MIS-C was associated with signatures of inflammation and T cell activation. The association of MIS-C with the combination of HLA A*02, B*35 and C*04 alleles suggests genetic susceptibility. MIS-C B cells showed higher mutation load than pCOVID-19 and pHC. These results identify distinct immunopathological signatures in pCOVID-19 and MIS-C that might help better define the pathophysiology of these disorders and guide therapy.
biochemistry & molecular biology,cell biology,medicine, research & experimental